Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations

被引:64
作者
Malbruny, B
Nagai, K
Coquemont, M
Bozdogan, B
Tambic Andrasevic, A
Hupkova, H
Leclercq, R [1 ]
Appelbaum, PC
机构
[1] UFR Med, Hop Cote Nacre, Microbiol Serv, Av Cote Nacre, F-14033 Caen, France
[2] Penn State Univ, Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA 17033 USA
[3] Univ Hosp Infect Dis Dr F Mihaljev, Dept Clin Microbiol, Zagreb 10000, Croatia
[4] St Cyril & Metol Hosp, Bratislava 85107, Slovakia
关键词
D O I
10.1093/jac/dkf038
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: Two clinical strains of Streptococcus pyogenes, 237 and 544, one isolated in Slovakia and the other in Croatia, that were resistant to azithromycin (MIC 8 and 2 mg/L, respectively) but susceptible to erythromycin (MIC 0.5 and 0.12 mg/L, respectively) did not contain any gene known to confer macrolide resistance by ribosomal modification (erm gene) or efflux [mef(A) and msr(A) genes]. The aim of the study was to determine the mechanisms of macrolide resistance in both strains. Methods: Portions of genes encoding ribosomal proteins L22 and L4, and 23S rRNA (domains II and V) in the two macrolide-resistant strains and in control strains susceptible to macrolides, were analysed by PCR and single-strand conformational polymorphism, to screen for mutations. The DNA sequences of amplicons from resistant strains that differed from those of susceptible strains, in terms of their electrophoretic migration profiles, were determined. Results: S. pyogenes 237 displayed a KG insertion after position 69 in ribosomal protein L4. S. pyogenes 544 contained a C2611U mutation in domain V of 23S rRNA. Conclusion: Mutations at a similar position in ribosomal protein L4 and 23S rRNA have been reported previously in macrolide-resistant pneumococci. This report shows that similar mutations can be found in macrolide-resistant S. pyogenes.
引用
收藏
页码:935 / 939
页数:5
相关论文
共 26 条
[1]   High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes:: results of a Spanish multicentre study in 1998 [J].
Alós, JI ;
Aracil, B ;
Oteo, J ;
Torres, C ;
Gómez-Garcés, JL .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (05) :605-609
[2]   Macrolide resistance phenotypes and genotypes in French clinical isolates of Streptococcus pneumoniae [J].
Angot, P ;
Vergnaud, M ;
Auzou, M ;
Leclercq, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (10) :755-758
[3]   The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution [J].
Ban, N ;
Nissen, P ;
Hansen, J ;
Moore, PB ;
Steitz, TA .
SCIENCE, 2000, 289 (5481) :905-920
[4]   Emergence of group a streptococcus strains with different mechanisms of macrolide resistance [J].
Bingen, E ;
Leclercq, R ;
Fitoussi, F ;
Brahimi, N ;
Malbruny, B ;
Deforche, D ;
Cohen, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1199-1203
[5]   Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients [J].
Bingen, E ;
Fitoussi, F ;
Doit, C ;
Cohen, R ;
Tanna, A ;
George, R ;
Loukil, C ;
Brahimi, N ;
Le Thomas, I ;
Deforche, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1453-1457
[6]   Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae [J].
Canu, A ;
Malbruny, B ;
Coquemont, M ;
Davies, TA ;
Appelbaum, PC ;
Leclercq, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :125-131
[7]  
Cha S, 2001, J Infect Chemother, V7, P81, DOI 10.1007/s101560100013
[8]   Rapid increase of resistance to erythromycin and clindamycin in Streptococcus pyogenes in Italy, 1993-1995 [J].
Cornaglia, G ;
Ligozzi, M ;
Mazzariol, A ;
Valentini, M ;
Orefici, G ;
Fontana, R .
EMERGING INFECTIOUS DISEASES, 1996, 2 (04) :339-342
[9]  
DAVIES TA, 2000, 40 INT C ANT AG CHEM, P65
[10]   Mutation in 23S rRNA responsible for resistance to 16-membered macrolides and streptogramins in Streptococcus pneumoniae [J].
Depardieu, F ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :319-323